Latest News
Learn about how researchers made a more accurate model of Alzheimer's disease using skin cells.
FDA approves of new Alzheimer's drug.
Learn about the first successful attempt to transplant lab-grown retinal ganglion cells (RGCs) into the eyes of mice to find a cure for glaucoma.
Learn about the new grants available this year for Macular Degeneration Research.
Learn about how a test allows clinicians to accurately detect signs of Alzheimer's Disease from a single blood draw.
A team of medical researchers and bioengineers developed a three-dimensional (3D) matrix model of wet age-related macular degeneration (AMD) that can help with understanding what causes the disease and find effective treatments.
A study of 131 older adults shows that driving behavior may be a good way to identify Alzheimer’s disease before other symptoms appear.
Johns Hopkins University’s Sheila West, Ph.D., Pharm.D., a world-renowned expert on environmental factors and disparities causing blindness, was this month awarded the 2020 Helen Keller Prize for Vision Research. The Prize, presented by BrightFocus Foundation and the Helen Keller Foundation for Research and Education, honors scientific discovery and excellence and is chosen by an independent awards committee. The award was delayed by one year because of the pandemic.
May 3, 2021—BrightFocus Foundation, a leading private funder of scientific research on diseases of mind and sight, today announced its 2021 named awards for macular degeneration and glaucoma research at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).
Tau is a protein that misfolds in Alzheimer’s disease, causing it to accumulate and aggregate in the brain, contributing to cognitive decline. Mice engineered to lack tau are protected from neuronal damage, and when levels of tau are reduced in mouse models of Alzheimer’s, their memory improves. Therefore, reducing tau may be a good therapeutic option for AD.